Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)

NCT02879097 is registered in ClinicalTrials.gov with Cipla BioTec Pvt. Ltd. as lead sponsor.

NCT NCT02879097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02879097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)
Lead sponsor
Cipla BioTec Pvt. Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2016
Completion date
May 31, 2018
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma